The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models

[1]  Y. M. Lee,et al.  Inhibition of Histone Deacetylase Attenuates Hypoxia-Induced Migration and Invasion of Cancer Cells via the Restoration of RECK Expression , 2010, Molecular Cancer Therapeutics.

[2]  Susan Groshen,et al.  DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines , 2009, BMC Medical Genomics.

[3]  N. L. La Thangue,et al.  Biomarkers for predicting clinical responses to HDAC inhibitors. , 2009, Cancer letters.

[4]  Y. Ho,et al.  Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. , 2009, World journal of gastroenterology.

[5]  William H. Bisson,et al.  Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. , 2009, Carcinogenesis.

[6]  Seon-Young Kim,et al.  In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer. , 2009, Anticancer research.

[7]  H. Lenz,et al.  Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells , 2009, International journal of cancer.

[8]  W-S Xu,et al.  Histone deacetylase inhibitors: Potential in cancer therapy , 2009, Journal of cellular biochemistry.

[9]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[10]  H. Prince,et al.  Clinical Studies of Histone Deacetylase Inhibitors , 2009, Clinical Cancer Research.

[11]  C. LeVea,et al.  A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Lenz,et al.  Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. , 2009, The oncologist.

[13]  Xiaohong Song,et al.  Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer. , 2009, Cancer letters.

[14]  A. Cox,et al.  Thymidine Selectively Enhances Growth Suppressive Effects of Camptothecin/Irinotecan in MSI+ Cells and Tumors Containing a Mutation of MRE11 , 2008, Clinical Cancer Research.

[15]  B. Teicher.  Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. , 2008, Biochemical pharmacology.

[16]  J. Mariadason.  HDACs and HDAC inhibitors in colon cancer , 2008, Epigenetics.

[17]  P. Dent,et al.  Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells , 2008, Clinical Cancer Research.

[18]  Hubert Vesselle,et al.  FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine. , 2007, Seminars in nuclear medicine.

[19]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[20]  Y. Oda,et al.  Expression profile of class I histone deacetylases in human cancer tissues. , 2007, Oncology reports.

[21]  K. Glaser.  HDAC inhibitors: clinical update and mechanism-based potential. , 2007, Biochemical pharmacology.

[22]  M. Reni,et al.  A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer , 2007, British Journal of Cancer.

[23]  Y. Pommier,et al.  Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks* , 2006, Journal of Biological Chemistry.

[24]  M. Yashiro,et al.  Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. , 2006, Oncology reports.

[25]  Paul Workman,et al.  In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. , 2006, Cancer research.

[26]  Andrew J. Wilson,et al.  Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer* , 2006, Journal of Biological Chemistry.

[27]  Z. Cao,et al.  CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo , 2006, Molecular Cancer Therapeutics.

[28]  L. Gerweck,et al.  Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics , 2006, Molecular Cancer Therapeutics.

[29]  A. Scarpa,et al.  Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation , 2006, Virchows Archiv.

[30]  P. Munster,et al.  Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ , 2005, Clinical Cancer Research.

[31]  P. Munster,et al.  Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid , 2004, Journal of cellular biochemistry.

[32]  P. Finn,et al.  Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.

[33]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  O. Witt,et al.  Induction of fetal hemoglobin synthesis by valproate: Modulation of MAPkinase pathways , 2002, American journal of hematology.

[35]  U. Haberkorn,et al.  A new precursor for the radiosynthesis of [18F]FLT. , 2002, Nuclear medicine and biology.

[36]  H. Manji,et al.  The Mood Stabilizer Valproic Acid Activates Mitogen-activated Protein Kinases and Promotes Neurite Growth* , 2001, The Journal of Biological Chemistry.

[37]  R. Gillies,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1998.0455 Enhancement of chemotherapy by manipulation of tumour pH , 2022 .

[38]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[39]  L. Hengst,et al.  Effects of p21Cip1/Waf1 at Both the G1/S and the G2/M Cell Cycle Transitions: pRb Is a Critical Determinant in Blocking DNA Replication and in Preventing Endoreduplication , 1998, Molecular and Cellular Biology.

[40]  R. Motzer,et al.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. , 1994, Journal of the National Cancer Institute.

[41]  C. Bartels,et al.  Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[43]  P. Munster,et al.  Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  F. Pulzer,et al.  Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. , 2001, Anticancer research.

[45]  Y. Pommier,et al.  Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs , 2000, Cancer Chemotherapy and Pharmacology.

[46]  L. Hengst,et al.  Erratum: Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication (Molecular and Cellular Biology 18:1 (629)) , 1998 .

[47]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.